Coronary Artery Stenosis Clinical Trial
Official title:
German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
The German-Austrian ABSORB Register shall provide an analysis of acute and long-term safety as well as therapy outcomes of the ABSORB (trade mark) bioresorbable vascular scaffold system in patients suffering from coronary artery disease.
The register collects prospective data regarding the quality of care of this therapy concept including specifically the following objectives: - Documentation of all consecutive patients having been treated with the ABSORB biore-sorbable vascular scaffold system under clinical real-world conditions - Documentation of indications, procedural results, and short and long-term outcomes - Documentation of the technical performance of ABSORB implant procedures - Collection of safety data, in particular documentation of hospital mortality, major non-fatal complications (especially myocardial infarction, Re-PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting), stroke, thrombosis) - Documentation of long-term patient safety marked by mortality and major non-fatal complications (especially myocardial infarction, Re-PCI or CABG, stroke, thrombosis) at 30 days, 6 months, 2 years and 5 years - Gathering of health economics data (capture of direct costs, especially with view to change of medication and outpatient/inpatient hospital services, and indirect costs) pre and post ABSORB implant - Gathering data on the quality of life pre and post ABSORB implant to document individual QoL dimensions as well as QALY (quality adjusted life year) data ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05133843 -
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
|
N/A | |
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Completed |
NCT01332591 -
Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.
|
N/A | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT00739466 -
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
|
Phase 2 | |
Completed |
NCT00531011 -
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Completed |
NCT01310309 -
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Not yet recruiting |
NCT06052670 -
Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
|
||
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT05393882 -
Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
|
||
Recruiting |
NCT06397820 -
Relation Between AI-QCA and Cardiac PET
|
||
Active, not recruiting |
NCT01960504 -
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
|
N/A | |
Completed |
NCT01721096 -
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
|
||
Active, not recruiting |
NCT01342822 -
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
|
Phase 4 | |
Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
Recruiting |
NCT05532605 -
Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i
|
N/A | |
Not yet recruiting |
NCT02946320 -
Optimal Predilatation Technique for BVS Implantation
|
Phase 3 | |
Completed |
NCT01136876 -
Kidney Damage in Patients With Moderate Fall in eGFR
|
Phase 4 | |
Completed |
NCT01249027 -
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
|
||
Terminated |
NCT01136915 -
Kidney Damage In Patients With Severe Fall In eGFR
|
Phase 4 |